Table 1.
Clinicopathologic features of reported Multifocal fibrosing thyroiditis cases
| Reference (n: number of cases) | Age, range (mean) | Sex (F:M) | Size of MFT lesions in mm, range (mean) | Number of MFT foci, range (mean) | MFT lymphoid infiltration (percentage of cases) | MFT multinucleated histiocytes (percentage of cases) | Thyroid pathology associated with MFT (Percentage of cases); average number of papillary carcinoma foci in MFT cases with PMC or PTCc | BRAF mutation in MFT (percentage of cases) |
|---|---|---|---|---|---|---|---|---|
| Poli F et al. Int J Surg Pathol. 2009;17(2):144 (n = 1) | 64 | F | NA | NA | NA | NA | FND (NH) 1/1(100) | NA |
| Frank R et al. Endocr Pathol. 2014;25(3):236-40a (n = 7) | 33–51 (42.7) | F:7;M:0 | NA | NA | NA | NA |
CL/HT: 7/7 (100) PMC: 2/7 (28.6) and PTC: 5/7 (71.4); 1.4 |
0/7 (0) |
| Fellegara G, Rosai J. Am J Surg Pathol. 2015;39(3):416–24 (n = 55)b | 15–71 (47.0) |
F:51; M:4 (12.7) |
0.4–15.1 (3.0) | 2–51 (16.0) |
38/38 (100) 14/38 (36.8) infiltration moderate-to-severe |
21/38 (55.2) 5/38 (13.2) numerous multinucleated histiocytes |
FND (NH): 19/55 (34.5) CL/HT: 14/55 (25.4) HT/GD: 6/55 (10.9) FA: 4/55 (7.3) FVPTC/NIFTP: 4/55 (7.3) FC: 2/55 (3.6) OC: 1/55 (1.8) PMC 16/55 (29.1) and PTC: 1/55 (1.8); 1.4 NTP: 4/55 (7.3) |
NA |
| Fellegara G, Rosai J. Am J Surg Pathol. 2015;39(6):870 (n = 1) | NA | NA | NA | 3 | NA | NA | PMC 1/1(100) | NA |
| Current case (n = 1) | 48 | F | 3–10 (5.6) | 5 (5) | 1/1 (100) moderate infiltration | 1/1 (100) | NTP 1/1(100) | 0/1 (0) |
| Total (n = 65) | 15–71 (46.8) |
F:60; M:4 (15.0) |
0.4–15.1 (3.1) | 2–51 (15.4) | 39/39 (100) | 22/39 (56.4) |
FND(NH): 20/65 (30.1) CL/HT: 21/65 (32.3) HT/GD: 6/65 (9.2) FA: 4/65 (6.1) FVPTC/NIFTP: 4/65 (6.1) FC: 2/65 (3.1) OC: 1/65 (1.5) PMC 19/65 (29.2) and PTC: 6/65 (9.2); 1.5 NTP: 5/65 (7.7) |
0/8 (0) |
F female, M male, MFT multifocal fibrosing thyroiditis, mm millimeters, PMC papillary thyroid microcarcinoma, PTC conventional papillary thyroid carcinoma larger than one centimeter, FND(NH) follicular nodular disease (nodular hyperplasia), CL/HT chronic lymphocytic/Hashimoto thyroiditis, HT/GD hyperthyroidism/Graves disease, FA follicular adenoma, FVPTC/NIFTP follicular variant PTC/noninvasive follicular thyroid neoplasm with papillary-like nuclear features, FC follicular carcinoma (encapsulated), OC oncocytic carcinoma, NTP no thyroid pathology (neither PMC nor other pathology), NA not available
aOnly MFT associated with PTC were selected for the study
bIn 38 of the 55 cases slides were available for review
cMore than one alteration (PMC or other pathology) may coexist in a given case